First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

Saved in:
Bibliographic Details
Title: First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Authors: Weiss L; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany. Electronic address: Lena.Weiss@med.uni-muenchen.de., Stintzing S; Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; DKTK Heidelberg, Partner Site Berlin, Germany., Modest DP; Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Stahler A; Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., von Weikersthal LF; MVZ Gesundheitszentrum St. Marien GmbH, Amberg, Germany., Reinacher-Schick A; Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany., Decker T; Onkologie Ravensburg, Ravensburg, Germany., Probst V; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Heinrich K; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Schwaner I; Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany., Kaiser F; VK&K Oncology GmbH, Landshut, Germany., Pihusch R; MVZ Praxis Pihusch, Rosenheim, Germany., Fuchs M; München Klinik Bogenhausen, Department of Gastroenterology, Hepatology and Gastrointestinal Oncology, Munich, Germany., Held S; ClinAssess GmbH, Leverkusen, Germany., Alig A; Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Gruenberger B; Universitätsklinikum Wiener Neustadt, Wiener Neustadt, Austria., Prager GW; Medical University of Vienna, Department of Medicine I, Vienna, Austria., Tougeron D; Department of Hepato-Gastroenterology, Poitiers University Hospital and University of Poitiers, Poitiers, France., Taieb J; CARPEM comprehensive cancer center, University Paris-Cité, department of Gastroenterology and GI Oncology, Hôpital Européen Georges Pompidou, Paris, France., Heinemann V; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2026 Jan; Vol. 232, pp. 116105. Date of Electronic Publication: 2025 Nov 13.
Publication Type: Comparative Study; Journal Article; Meta-Analysis; Comparative Study
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.116105